London: GSK plc and Boston Pharmaceuticals, a clinical stage biopharmaceutical company developing highly targeted therapies ...

Aiming to expand its hepatology portfolio, UK pharma major GSK (LSE: GSK) yesterday announced that it has entered into an ...

GSK will gain access to efimosfermin by acquiring Boston’s subsidiary BP Asset IX for $1.2bn upfront and up to $800m in ...

GSK to buy Boston Pharma’s efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of SLD: London, UK Thursday, May 15, 2025, ...

The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their ...

Through the Boston Pharma deal, GSK aims to strengthen its pipeline, as some of its key products are nearing the end of their exclusivity period.

This marks AbbVie’s second major siRNA deal following its $1.4bn acquisition of Aliada Therapeutics last year.

May 14 (Reuters) - GSK (GSK.L), opens new tab will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm Boston Pharmaceuticals ...

USA-based Inozyme Pharma, a biopharma developing innovative therapeutics for rare diseases that affect bone health and blood ...

Liver fibrosis is a gradually worsening condition marked by excessive collagen buildup resulting from ongoing liver damage. This abnormal wound-healing response distorts the liver's structure, ...